Last reviewed · How we verify

NCT04535700

Clinical Trial of Pioglitazone Treatment in Patients With Type 2 Diabetes Mellitus and Covid-19

Completed Phase 4 Last updated 31 May 2023
What this trial tests

Phase 4 trial testing Pioglitazone 30 mg in Type 2 Diabetes in 8 participants. Completed in 10 January 2022.

Timeline
18 September 2020
Primary endpoint
19 November 2021
10 January 2022

Quick facts

Lead sponsorFundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal
PhasePhase 4
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment8
Start date18 September 2020
Primary completion19 November 2021
Estimated completion10 January 2022
Sites1 location across Spain

Drugs / interventions tested

Conditions studied

Sponsor

Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal

Who can join

18 and older, any sex, with Type 2 Diabetes. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The treatment with pioglitazone added to the standard treatment of patients with DM2 hospitalized for COVID-19 may produce a decrease in the number of patients who progress to a second phase of severe systemic inflammation.

Publications & conference data

7 peer-reviewed publications reference this trial (live from Europe PMC):

  1. An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment.
    Drożdżal S, Rosik J, Lechowicz K, Machaj F, et al · · 2021 · cited 186× · PMID 34991982 · DOI 10.1016/j.drup.2021.100794
  2. The mechanism underlying extrapulmonary complications of the coronavirus disease 2019 and its therapeutic implication.
    Ning Q, Wu D, Wang X, Xi D, et al · · 2022 · cited 64× · PMID 35197452 · DOI 10.1038/s41392-022-00907-1
  3. Cell deaths: Involvement in the pathogenesis and intervention therapy of COVID-19.
    Li X, Zhang Z, Wang Z, Gutiérrez-Castrellón P, et al · · 2022 · cited 58× · PMID 35697684 · DOI 10.1038/s41392-022-01043-6
  4. COVID-19 metabolism: Mechanisms and therapeutic targets.
    Wang T, Cao Y, Zhang H, Wang Z, et al · · 2022 · cited 33× · PMID 35958432 · DOI 10.1002/mco2.157
  5. COVID-19 and renin angiotensin aldosterone system: Pathogenesis and therapy.
    Babajani F, Kakavand A, Mohammadi H, Sharifi A, et al · · 2021 · cited 16× · PMID 34869917 · DOI 10.1002/hsr2.440
  6. The role of reactive oxygen species in severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) infection-induced cell death.
    Xie J, Yuan C, Yang S, Ma Z, et al · · 2024 · cited 14× · PMID 39516736 · DOI 10.1186/s11658-024-00659-6
  7. The COVID-19-diabetes mellitus molecular tetrahedron.
    Mahmudpour M, Vahdat K, Keshavarz M, Nabipour I. · · 2022 · cited 9× · PMID 35067816 · DOI 10.1007/s11033-021-07109-y

Verify or expand the search:

Other trials of Pioglitazone 30 mg

Trials testing the same drug.

Other recruiting trials for Type 2 Diabetes

Currently open trials in the same condition.

Other Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04535700.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing